Pediatric Cancer Clinical Trial Finder
We believe that patients and families should have tools available to help make the search for treatments easier. For that reason, we’ve developed a Pediatric Cancer Clinical Trial Navigator for CAR T-cell therapy and other immunotherapy treatments. Use the filters to display relevant trials. Clicking on a card will allow you to access more detailed information, including contact information, for each clinical trial.
Genetic
Biological
Drug
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
U.S.
TX
Recruiting
Learn More
Genetic
Biological
Drug
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma (GRAIN)
U.S.
TX
Active, not recruiting
Learn More
Genetic
Biological
Drug
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19/ALLO-501
U.S.
CA,
PA,
TX,
MA
Europe
Japan
Other
Learn More
Genetic
Biological
Drug
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
U.S.
MA,
PA,
TX
Europe
Japan
Recruiting
Learn More
Genetic
Biological
Drug
Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4)
Canada
U.S.
CA,
CO,
FL,
MD,
IL,
MN,
OH,
PA,
TN,
TX,
VA,
WI
Europe
Recruiting
Learn More
Genetic
Biological
Drug
Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)
U.S.
PA
Completed
Learn More
Genetic
Biological
Drug
CD19 CART Long Term Follow Up (LTFU) Study
Canada
Australia
U.S.
AZ,
CA,
GA,
IL,
MN,
KS,
MI,
NY,
OH,
NC,
PA,
TX,
MO,
OR,
UT,
WI
Europe
Recruiting
Learn More
Genetic
Biological
Drug
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
U.S.
PA
Active, not recruiting
Learn More
Genetic
Biological
Drug
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1 (c2591) T Cells in HLA-A2+ Patients With Synovial Sarcoma
U.S.
CA,
FL,
MD,
MA,
MO,
NY,
PA,
TX
Active, not recruiting
Learn More
Genetic
Biological
Drug
Study of Efficacy and Safety of Tisagenlecleucel in High Risk (HR) B-cell Acute Lymphoblastic Leukemia (ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy (CASSIOIPEIA)
Canada
U.S.
PA,
TX,
MD
Europe
Recruiting
Learn More
Genetic
Biological
Drug
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
U.S.
TX
Recruiting
Learn More